We describe the use of nitric oxide as an oxygen-sparing strategy in the context of prior bleomycin exposure. A 27-year-old male, previously treated with bleomycin for a testicular germ cell tumour, presented with severe acute respiratory distress syndrome on the second postoperative day following an extensive retroperitoneal dissection. The mechanism of bleomycin toxicity and potential benefits of nitric oxide in this situation are considered.
CASE HISTORY
A 27-year-old male presented with a recurrence of a testicular germ cell tumour, which had initially been diagnosed in December 2002 and treated by radical left orchidectomy. Based on histology, a surveillance strategy was adopted post-surgery. In May 2005 the patient represented with a large retroperitoneal lymph node mass and an associated elevation of tumour markers (AFP 262 ug/l, BHCG 1000 IU/l).
He underwent four cycles of BEP therapy (Bleomycin, Etoposide and Cisplatin) which was completed by August 2005. His cumulative dose of bleomycin was 360 mg. Despite a 50% reduction in tumour size, his tumour markers continued to rise and he was then treated with a G-tip regimen (Paclitaxel, Ifosfamide and Cisplatin).
On completion of this chemotherapy in December 2005, elective surgery for resection of residual retroperitoneal tumour was planned. Respiratory function studies demonstrated a moderate decrease in his diffusion constant (KO) from 5.99 prior to bleo-mycin, to 4.84 ml/min/mmHg/l post-bleomycin. Surgery was complicated and prolonged, lasting requiring transection and repair, with a clamp time of 72 minutes. Bilateral ileo-femoral embolectomies were required post-aortic repair with subsequent reperfusion disturbance, including a serum lactate of 7.0 mmol/l. Left nephrectomy was also performed for tumour invasion. Intraoperatively and during transfer the patient was managed with a FiO 2 of 0.25 with intermittent increases to 0.5, lasting less than an hour. Six units of blood were transfused Intraoperative haemodynamic lability resulted in alternating use of noradrenaline, metaraminol and glyceryl trinitrate.
Postoperatively the patient was electively transferred to the intensive care unit. At this time the patient was fully ventilated with a FiO 2 of 0.21 and a MAP of 65 mmHg supported by a noradrenaline infusion at 5 ug/min. The patient was normothermic and producing >50 ml/hr of urine, despite a creatinine of 192 umol/l. Hydrocortisone 100 mg was continued six hourly given the left nephrectomy, extensive surgery and potential compromise to adrenal perfusion. For the next 18 hours the patient was relatively stable, followed by an acute deterioration marked by profound respiratory failure and shock. HCO 3 22 mmol/l and SaO 2 86%. A protective ventilation strategy was utilised, with tidal volumes of 400 ml, PEEP of 15 cmH 2 O and plateau pressures of less 30 cmH 2 O. Nitric oxide (NO) was commenced at 10 PPM, delivered by an Inovent delivery system (Dräger Medical ® Ohmeda inc., 110 Allen Road, PO Box 804, Liberty Corner, New Jersey, U.S.A.). This system is an integrated, single unit designed for the delivery and monitoring of inhaled nitric oxide. It delivers a user-selectable, constant concentration of NO even with varying ventilator settings and modes. A PaO 2 >60 mmHg was targeted at the lowest possible fraction of inspired oxygen and nitric oxide was titrated to this end point. Figure 1 demonstrates the nitric oxide facilitated reduction in the fraction of inspired oxygen. Clinically there was no suggestion of ongoing bleeding with haemoglobin maintained, without support, at 120 g/l. He was commenced on a vasopressin infusion at 0.04 U/min to minimise the rising noradrenaline requirement. An intraabdominal compartment syndrome was excluded with repeated bladder pressures recorded below 10 cmH 2 O.
A pulse contour continuous cardiac output catheter (PiCCO, Pulsion Medical Systems, Munich, Germany) demonstrated features of distributive shock with a cardiac index of 7 l/m 2 /min (Normal range 3.0-5.0), GEDVI 796 ml/m 2 (Normal range 680-800), EVLWI 9.0 ml/kg (Normal range 3-7) and SVRI of 600 dyn. s.cm -5 /m 2 (Normal range 1700-2400). Transthoracic echocardiography was performed revealing essentially normal cardiac function, with an ejection fraction of 58%. Despite a full septic workup, no organism was isolated and the patient was empirically treated with the respiratory failure resolved allowing the gradual day the patient was successfully extubated and by day seven was suitable for discharge to the ward.
DISCUSSION
The severe respiratory failure occurring 18 hours postoperatively in this patient was likely multifactorial, including elements of reperfusion injury and possibly bleomycin-induced pneumonitis. Unfortunately there is no available test to secure the diagnosis of acute bleomycin toxicity and there exist a number of possibilities for this patient's respiratory failure. Oxygen-induced bleomycin pneumonitis may have been the result of intermittent increases in the inspired fraction of oxygen, both intraoperatively and in the initial phase of the intensive care admission. Regardless of the aetiology of the acute respiratory distress syndrome, it was imperative to minimise further toxic effects of oxygen exposure in the setting of a bleomycin-primed patient. We believe this to further oxygen toxicity in bleomycin-treated patients. Bleomycin is an anti-tumour agent isolated from a strain of Streptomyces verticillus. It is used to treat lymphomas, germ cell tumours and squamous cell carcinomas of the head and neck. It is mildly myelotoxic, but its main disadvantage is potential lung toxicity, which occurs in up to 40% of patients who then have a reported 1-10% mortality rate 1 .
The cytotoxic agent bleomycin is feared for its induction of sometimes fatal pulmonary toxicity, also known as bleomycin-induced pneumonitis (BIP). diagnosis is established by a combination of clinical symptoms, radiographic alterations and pulmonary function test results, while other disorders resembling BIP have to be excluded. There are no proven effective treatments for BIP in humans, although corticosteroids are widely applied. When patients survive BIP, they almost always recover completely with normalisation of radiographic and pulmonary function abnormalities 2 .
Bleomycin is composed of two major structures, which facilitate binding both ferrous (Fe ++ ) iron and the deoxyribonucleic acid (DNA) within the cell. A bithiazole portion intercalates with the DNA helix and a pyrimidine and imidazole component binds to iron and oxygen 3 . Upon exposure to molecular oxygen, the ferrous bleomycin compound is oxidised to an activated ferric (Fe +++ ) bleomycin compound and the bound molecular oxygen is reduced to oxygen free radicals, including superoxide and hydroxyl radicals. The combination of activated (Fe +++ ) bleomycin and release of oxygen free radicals in close proximity to the partially intercalated bleomycin DNA complex causes DNA cleavage and subsequent cell damage 4 .
The initial injury after bleomycin is believed to occur within the pulmonary endothelium. The capillary endothelium becomes separated from the basement membrane, resulting in increased permeability and interstitial oedema. Bleomycin then reaches the alveolar epithelial cells in high concentrations, resulting in necrosis of the type I alveolar by increased collagen synthesis and decreased colla-5 .
bleomycin-treated patients and these effects persisted for up to 64 days of observation 6 . Several factors are considered to increase the risk of bleomycin pulmonary toxicity, including total dose, radiation therapy, age, other concurrent chemopulmonary toxicity occurs at total doses of more than 450 mg, but severe pulmonary toxicity can occur with much smaller doses 7, 8 . High oxygen concentrations have been implicated in potentiating lung damage in patients who have received bleomycin 9,10 , although the mechanism is not fully understood. Previous bleomycin treatment sensitises the lung to concentrations of oxygen that are not usually damaging. The interval time, after which oxygen can safely be given after bleomycin, has not been established. In a retrospective study of 14 patients, Douglas and Coppin described pulmonary interstitial changes in the X-rays of a woman exposed three months after she had received her last dose of bleomycin 11 . According to Hulbert et al, the shorter the time between the last dose of bleomycin and exposure to hyperoxia (FiO 2 >0.25), the greater the risk of respiratory compromise 12 . Some patients receiving bleomycin for testicular cancer, when given high-dose nitrous oxide mixtures for anaesthesia, have been known to develop acute respiratory distress syndrome, presumably on the basis of the oxygen content.
A myriad of agents and strategies have been employed to prevent or minimise bleomycin toxicity including plant phenolics 13 , protein thioredoxin 14 , taurine and niacin 15 , metalloporphyrin 16 , pen-toxifylline 17 , ibuprofen 18 and steroids 19 . Drugs that are not capable of affecting bleomycin pneumonitis include enoxaparin, pentoxifylline and linomide 2 . The results of systemic corticosteroids in this setting remain controversial, although they are often empirically instituted 20 . primed patient. We believe the mechanism of action and potential oxygen-sparing effect of nitric oxide may well have been useful in the described patient. Inhaled nitric oxide has emerged as a potential therapy for acute respiratory distress syndrome. This is due to the reduction of pulmonary vascular resistance, without affecting systemic blood pressure. Inhaled the lungs by dilating primarily those pulmonary vessels that are ventilated 21 . This reduces intrapulmonary shunting, improves ventilation-perfusion matching, and therefore increases arterial oxygenation. These effects are in contrast to intravenous vasodilators that worsen oxygenation 22 .
Two small, single-centre studies and four multicentre, randomised, placebo-controlled trials have failed to determine the therapeutic role of inhaled nitric oxide in patients with acute respiratory failure 23 . Dellinger et al demonstrated a 20 mmHg increase in PaO 2 in 60% of patients treated with nitric oxide, but 24 . The mechanism of the endothelial damage, prob-ably the primary event in the development of bleomycin pneumonitis, is not exactly known, but evidence is mounting that the induction of cytokines and free radicals is involved. These cytokines and free radicals can damage endothelial cells. Furthermore, the induced cytokines activate lymphocytes and upregulate adhesion molecules on endothelial cells, lymphocytes also contribute to the endothelial damage by inducing apoptosis 2 . The effect of inhaled been fully elucidated. Weinberger et al 25 demonstrated that inhaled nitric oxide primes lung macrophages to release reactive oxygen and nitrogen intermediates. They proposed increased production of these mediators by macrophages may contribute to tissue injury. While several other animal studies have demonstrated a protective effect of inhaled nitric oxide, an eloquent rabbit model by Koh showed that inhaled nitric oxide attenuated lipopolysaccharide lung injury, which they speculated was secondary to decreased intrapulmonary production of NO, reactive oxygen species, and nuclear factor-[kappa]B 26 .
Inhaled nitric oxide may modulate the acute and dysfunction of the alveolar-capillary membrane that characterises acute respiratory distress syndrome. The protective effects of nitric oxide could derive example, by attenuation of the respiratory burst and neutrophil-derived oxidative stress 23 . Inhaled nitric oxide has decreased the accumulation of neutrophils in the pulmonary vasculature and air space in animal models of acute lung injury, consistent with its known effects on the adhesion and deformability of neutrophils in vitro 27 .
inhaled nitric oxide in the setting of the bleomycinprimed patient may simply be a function of minimising deleterious oxygen exposure or there may exist a more
CONCLUSION
We have described a case of severe acute respiratory distress in a bleomycin-primed patient, exposed to moderate hyperoxia. The use of nitric oxide provided an oxygen sparing strategy to minimise further hyperoxia. The proposed mechanism of bleomycin oxide, make this a plausible therapeutic option which requires further investigation.
